{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:30:54Z","timestamp":1773297054076,"version":"3.50.1"},"reference-count":21,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2010,2,26]],"date-time":"2010-02-26T00:00:00Z","timestamp":1267142400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2010,6]]},"abstract":"<jats:p> <jats:bold>WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT<\/jats:bold> <\/jats:p><jats:p>\u2022\u2003Seretide (GlaxoSmithKline, UK) is a combination inhaler which contains both fluticasone (FP) and salmeterol (SM).<\/jats:p><jats:p>\u2022\u2003A generic fluticasone\/salmeterol (FP\/SM) combination inhaler (Neolab, UK) has recently been developed.<\/jats:p><jats:p>\u2022\u2003Determination of therapeutic equivalence is essential in the development of generic products.<\/jats:p><jats:p> <jats:bold>WHAT THIS STUDY ADDS<\/jats:bold> <\/jats:p><jats:p>\u2022\u2003This paper determines that <jats:italic>in vitro<\/jats:italic> fine particle dose may not predict pharmacokinetic and systemic pharmacodynamic outcomes.<\/jats:p><jats:p>\u2022\u2003This paper shows that the generic and reference products were equivalent in terms of FP, but not SM pharmacokinetics.<\/jats:p><jats:p>\u2022\u2003No significant differences were found between generic and reference products in terms of either adrenal suppression or hypokalaemia.<\/jats:p><jats:p><jats:bold>AIM<\/jats:bold> To compare a test version of HFA fluticasone\/salmeterol (FP\/SM) combination inhaler (Neolab, UK) with the reference product Seretide (GlaxoSmithKline, UK).<\/jats:p><jats:p><jats:bold>METHODS<\/jats:bold> An <jats:italic>in vitro<\/jats:italic> Anderson cascade impactor was used to compare the fine particle dose (&lt;4.7\u2003\u00b5m). Two separate randomized cross\u2010over studies were performed to compare the systemic bioavailability of test <jats:italic>vs.<\/jats:italic> reference (T <jats:italic>vs<\/jats:italic>. R) formulations of FP\/SM 250\/25\u2003\u00b5g pMDI in healthy volunteers. In study 1 blood pharmacokinetic analysis using oral charcoal block was performed over 24\u2003h following a single dose of four puffs via pMDI alone. In study 2 systemic bioactivity was measured following single doses of four and eight puffs via a spacer device: serum potassium (K<jats:sup>+<\/jats:sup>) to reflect SM, and overnight urinary cortisol\u2003:\u2003creatinine (OUCC) for FP. An early pharmacokinetic profile was also assessed over 120\u2003min.<\/jats:p><jats:p><jats:bold>RESULTS<\/jats:bold> The <jats:italic>in vitro<\/jats:italic> fine particle dose was similar for test <jats:italic>vs.<\/jats:italic> reference pMDI alone and via spacer. The results of both studies were consistent: No significant differences between formulations were seen in terms of FP kinetics. Analysis of SM kinetics revealed superiority of the test product. No significant dose\u2013response or difference in T\u2003:\u2003R ratio was noted for OUCC. Fall in K<jats:sup>+<\/jats:sup> revealed a significant dose\u2013response with a non\u2010significant T\u2003:\u2003R ratio.<\/jats:p><jats:p><jats:bold>CONCLUSIONS<\/jats:bold> The <jats:italic>in vitro<\/jats:italic> fine particle dose may not predict pharmacokinetic and systemic pharmacodynamic outcomes. Single dosing studies with fluticasone\/salmeterol 250\/25\u2003\u00b5g via pMDI or with spacer showed pharmacokinetic equivalence with FP, but not SM. No significant difference between formulations was seen with either adrenal suppression or hypokalaemia.<\/jats:p>","DOI":"10.1111\/j.1365-2125.2010.03655.x","type":"journal-article","created":{"date-parts":[[2010,2,26]],"date-time":"2010-02-26T09:41:24Z","timestamp":1267177284000},"page":"637-644","source":"Crossref","is-referenced-by-count":15,"title":["Systemic bioavailability of hydrofluoroalkane (HFA) formulations of fluticasone\/salmeterol in healthy volunteers via pMDI alone and spacer"],"prefix":"10.1111","volume":"69","author":[{"given":"Karine L.","family":"Clearie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter A.","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sriram","family":"Vaidyanathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeannine","family":"Du Bois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haylene","family":"Nell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian J.","family":"Lipworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,5,10]]},"reference":[{"key":"e_1_2_6_2_2","unstructured":"Global Strategy for Asthma Management and Prevention Global Initiative for Asthma (GINA).From the Global Strategy for Asthma Management and Prevention Global Initiative for Asthma (GINA).2007. Available athttp:\/\/www.ginasthma.org(last accessed 24 August 2009)."},{"key":"e_1_2_6_3_2","unstructured":"British Guideline on the management of asthma. BTS\/SIGN guidelines revised edition 2008. Available athttp:\/\/www.brit\u2010thoracic.org.uk(last accessed 24 August 2009)."},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2004.039180"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.153.5.8630590"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2003.1558"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200401-033OC"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2003.38"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/1099-0496(200008)30:2<97::AID-PPUL4>3.0.CO;2-P"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.116.4.935"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.54.7.614"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1997.d01-1425.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3003.1999.13b38.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2004.11.005"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)62914-6"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2009.02.001"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1999.00652.x"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(94)90045-0"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.50.5.497"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.156.1.9610113"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)91265-7"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2001.01362.x"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2010.03655.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2010.03655.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T08:08:56Z","timestamp":1697443736000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2010.03655.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,10]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["10.1111\/j.1365-2125.2010.03655.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03655.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,10]]}}}